Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
批准号:
9919516
负责人:
VASSILIKI A BOUSSIOTIS
金额:
$57.1万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-14 至 2022-05-31
关键词:
ATP Citrate (pro-S)-LyaseAcetyl Coenzyme AAcetylationAffectAntigensBioenergeticsBiogenesisCD8-Positive T-LymphocytesCD8B1 geneCell Differentiation processCell TherapyCell physiologyCellsChIP-seqChromatinCitric Acid CycleDNAEnzymesEpigenetic ProcessEventGene Expression RegulationGenerationsGenesGeneticGenetic TranscriptionGlucoseGlutamatesGlutamineGlycolysisHexokinase 2Histone AcetylationHistonesHumanImmune responseImmunityInfectionLabelLeadListeria monocytogenesLongevityMalignant NeoplasmsMediatingMemoryMetabolicMetabolismMethodsMitochondriaMolecularMusOutcomeOxidative StressPharmacologyPhenotypeProductionPropertyPyruvateRoleSolid NeoplasmT cell differentiationT memory cellT-LymphocyteTimeTracerWarburg Effectaerobic glycolysisbasebisulfite sequencingcancer cellcancer immunotherapydemethylationembryonic stem cellepigenetic regulationfatty acid oxidationimmunoregulationimprintimprovedinhibitor/antagonistlactate dehydrogenase Aleukemia treatmentmetabolomicsneoplastic cellnovelnovel strategiespathogenpreferencepreventprogramsresponsestable isotopestem cellsstem-like cellstemnesstranscriptome sequencingtumortumor growthtumor microenvironmenttumorigenesiswhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Divergence in the metabolic reprogramming is critical to effectively imprint distinct T cell fates. To meet their
bioenergetic demands, T effector (TEFF) cells use aerobic glycolysis leading to lactate production (the Warburg
effect), whereas T memory cells (TM) switch to fatty acid oxidation (FAO). It remains poorly understood how
transition of TEFF to TM cells correlates with simultaneous metabolic reprogramming. It is also unclear whether
glycolysis itself regulates such transition events. The lactate dehydrogenase-A (LDH-A) enzyme catalyzes the
conversion of pyruvate to lactate in the last step of glycolysis, a hallmark of the Warburg effect. LDH-A is
upregulated in human cancers and is associated with aggressive tumor outcomes. Conversely, inactivation of
LDH-A in tumor cells results in decreased tumorigenesis and regression of established tumors. We generated
LDH-Aflox/floxCD4-Cre (LDH-A-/-) and LDH-Aflox/flox (LDH-Acon) mice, in which LDH-A is deleted only in T cells, to
study how targeting the hallmark step of the Warburg effect would affect T cell function. Antigen-specific CD8+
LDH-A-/- TEFF rapidly expanded, differentiated to TCM and TSCM and displayed potent response on antigen
mediated re-challenge. Moreover, tumor-infiltrating CD8+ LDH-A-/- T cells retained robust mitochondrial function
in the tumor microenvironment and inhibited tumor growth. Metabolite tracer studies revealed that LDH-A-/-
CD8+ T cells had enhanced glucose flux, elevated intermediates of glycolysis, TCA cycle, and glucose-derived
acetyl-coA but diminished usage of glutamine for TCA anaplerosis. This altered metabolic preference has been
identified in embryonic stem cells (ES) cells, where it promotes histone/DNA demethylation by aKG-dependent
demethylases and maintains stemness. Moreover, similarly to ES cells, LDH-A-/- CD8+ T cells had increased
histone acetylation mediated via glycolysis-derived acetyl-CoA. These metabolism-driven epigenetic changes
might be responsible for the rapid differentiation of LDH-A-/- cells to TCM and TSCM, which have stemness
features. Our findings support the novel hypothesis that glycolysis has a key role on memory T cell
differentiation by generating pyruvate and that it is the pyruvate-acetyl-CoA step not the pyruvate-lactate step,
which contributes to the generation of cellular identity and has a mechanistic role on the transcriptional and
epigenetic state of T cells. Understanding and recapitulating this metabolic state might provide a novel method
to generate potent antigen-specific TEFF and TM cells for cancer immunotherapy. To investigate this, we will
pursue the following specific aim to determine:
1. How LDH-A mediated metabolic changes affect the differentiation program of tumor-specific T cells.
2. How LDH-A targeting impacts the epigenetic regulation of TM cell differentiation.
3. How LDH-A targeting affects the properties and function of tumor-specific T cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.
-
批准号:10681034
-
项目类别:
-
资助金额:$67.26万
-
财政年份:2023
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy
-
批准号:10605878
-
项目类别:
-
资助金额:$72.26万
-
财政年份:2023
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
The effects of PD-1 on tumor-mediated “emergency” myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity
-
批准号:10330481
-
项目类别:
-
资助金额:$59.12万
-
财政年份:2020
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
The effects of PD-1 on tumor-mediated “emergency” myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity
-
批准号:10547788
-
项目类别:
-
资助金额:$59.12万
-
财政年份:2020
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
-
批准号:10524100
-
项目类别:
-
资助金额:$4.44万
-
财政年份:2018
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
-
批准号:10198866
-
项目类别:
-
资助金额:$64.89万
-
财政年份:2018
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
-
批准号:10431932
-
项目类别:
-
资助金额:$63.6万
-
财政年份:2018
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Advancing Treatment Outcomes in Malignant Glioma by Integrating Immunotherapy and Standard of Care using Genetically Engineered Mice that Recapitulate Molecular Feature of Human Glioma
-
批准号:10377182
-
项目类别:
-
资助金额:$4.53万
-
财政年份:2018
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
-
批准号:10152529
-
项目类别:
-
资助金额:$57.1万
-
财政年份:2017
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Effects of PGE2 on Reconstitution of Hematopoiesis and Immunity after UCBT
-
批准号:8985871
-
项目类别:
-
资助金额:$37.47万
-
财政年份:2013
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
The role of RIAM in T cell immunity and tolerance
-
批准号:8707612
-
项目类别:
-
资助金额:$40.89万
-
财政年份:2013
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT
-
批准号:8588715
-
项目类别:
-
资助金额:$57.39万
-
财政年份:2013
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT
-
批准号:9314786
-
项目类别:
-
资助金额:$35.52万
-
财政年份:2013
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT
-
批准号:9272856
-
项目类别:
-
资助金额:$89.4万
-
财政年份:2013
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Effects of PGE2 on reconstitution of hematopoiesis and immunity after UCBT
-
批准号:8703046
-
项目类别:
-
资助金额:$52.08万
-
财政年份:2013
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Prevention of acute GvHD by inhibition of cdk2
-
批准号:8093452
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2011
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Prevention of acute GvHD by inhibition of cdk2
-
批准号:8250339
-
项目类别:
-
资助金额:$25.32万
-
财政年份:2011
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Reconstitution of T cell immunity after UCB transplantation: The role of Treg
-
批准号:7405249
-
项目类别:
-
资助金额:$39.19万
-
财政年份:2008
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Reconstitution of T cell immunity after UCB transplantation: The role of Treg
-
批准号:7694977
-
项目类别:
-
资助金额:$39.07万
-
财政年份:2008
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
Expression and Function of Tob in T Lymphocytes
-
批准号:7060340
-
项目类别:
-
资助金额:$32.59万
-
财政年份:2005
-
负责人:VASSILIKI A BOUSSIOTIS
-
依托单位:
海外基金